American Society of Clinical Oncology submissions |
Year |
Month |
| Bramwell VH, Pritchard KI, Tu D, Tonkin K, Vachhrajani H, Arnold JRA, Vandenber T, Graham B, Shepherd L. Tamoxifen (T) compared to placebo (P), after adjuvant chemotherapy (CT), in premenopausal women with early breast cancer (EBC): Interim results of NCIC-CTG, MA.12. 2007 Annual Meeting, ASCO, Chicago, IL, USA |
2007 |
May |
| Lipton A, de Boer R, Figueroa J, Paterson A, Steger GG, Tonkin KS, Fan M, Kinsey A, Jun S. Phase II study of Denosumab in breast cancer patients with bone metastases naive to intravenous bisphosphonate therapy: extended efficacy and safety analysis. American Society of Clinical Oncology Meeting, Chicago, Illinois |
2007 |
May |
| Pituskin E, Martin-McDonald K,Williams B, & Au H-J. The experience of a sample of Canadian men with breast cancer. ASCO Proceedings; abstract 10549. |
2006 |
Jun |
| Jones LW, Haykowsky M, Carolyn J, Peddle CY, Joy AA, Pituskin EA, Tkachuk EM, Courneya C, Slamon DJ, Mackey JR. Cardiovascular Risk Profile of HER2/neu Positive Breast Cancer Patients Treated with Doxorubicin and/or Trastuzumab Containing Adjuvant chemotherapy. 2006 ASCO Annual Meeting Proceedings; abstract #666. |
2006 |
Jun |
| Jones LW, Haykowsky M, Peddle CJ, Joy AA, Pituskin EN, Tkachuk LM, Courneya C, Slamon DJ, Mackey JR. Cardiovascular Risk Profile of HER2/neu Positive Breast Cancer Patients Treated with Doxorubicin and/or Trastuzumab Containing Adjuvant Chemotherapy. 2006 ASCO Annual Meeting Proceedings; abstract 666. |
2006 |
Jun |
| BS Abdulkarim, Z Gabos, R Singha, J Hanson, N Chauhan, J Hugh, J Mackey. Prognostic significance of HER-2/neu over-expression on the incidence of brain metastasis in newly diagnosed breast cancer. 2006 ASCO Meeting Proceedings, page 40, Abstract #649 |
2006 |
|
| R Lai, ED Hsi, J Mackey, S Jung, JL Johnson, JR Cook, D Jones, JW Said, BD Cheson, NL Bartlett. High expression of nucleoside transporter hENT1 predicts a worse event-free survival in relapsed/refractory Hodgkin Lymphoma patients treated with gemcitabine, vinorelbine, and liposomal doxorubicin-A CALGB 5984 correlative study. 2006 ASCO Annual Meeting Proceedings, page 442, Abstract #7581 |
2006 |
|
| CJ Peddle, ND Eves, KS Courneya, M Haykowsky, JR Mackey, AA Joy, TJ Reiman, TW Winton, LW Jones. Effects of presurgical exercise training on exercise capacity in operable lung cancer: A pilot study. 2006 ASCO Annual Meeting Proceedings, page 670, Abstract #17047 |
2006 |
|
| Sawyer MB, Damaraju S, Pituskin E, Carter SJ, Dufour J, Carandang D, Hanson J, Mackey JR. Effects of cytochrome P450 polymorphisms on tamoxifen metabolism. Abstract 2055. |
2005 |
May |
| The role of Adjuvant Docetaxel in Early Stage Breast Cancer. JR Mackey, ASCO Educational Book, pp 14 - 21. |
2005 |
May |
| Mackey JR, Damaraju S, Pituskin E, Scarfe AG, Tonkin K, Au H-J, Koski S, Joy AA, Hanson J, Sawyer MB. Pharmacogenetics of epirubicin and uridine glucuronosyltransferase 2B7 in early breast cancer patients. Abstract 2015. |
2005 |
May |
| Vogel C, Mackey JR, Martin M. The role of growth factor support following neutropenic events in early stage breast cancer (BC) patients treated with adjuvant docetaxel, doxorubicin, and cyclophosphamide (TAC): A sub-analysis of BCIRG 001. Proceedings of ASCO 23 page 46 Abstr. 677. New Orleans, June 5-8, 2004 |
2004 |
Jun |
| Jones LW, Courneya KS, Peddle C, Mackey JR. Oncologists’ attitudes towards recommending exercise to cancer patients: A Canadian national survey. Proceedings of ASCO 23 page 759 Abstr. 8138. New Orleans, June 5-8, 2004. |
2004 |
Jun |
| Jones LW, Courneya KS, Peddle C, Mackey JR. Oncologists’ attitudes towards recommending exercise to cancer patients: A Canadian national survey. Proceedings of ASCO 23 page 759 Abstr. 8138. New Orleans, June 5-8, 2004. |
2004 |
Jun |
|
